HomeCompareDCCPY vs ABBV

DCCPY vs ABBV: Dividend Comparison 2026

DCCPY yields 5.03% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DCCPY wins by $174.0K in total portfolio value· pulled ahead in Year 4
10 years
DCCPY
DCCPY
● Live price
5.03%
Share price
$29.68
Annual div
$1.49
5Y div CAGR
41.9%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$276.3K
Annual income
$126,626.42
Full DCCPY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — DCCPY vs ABBV

📍 DCCPY pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDCCPYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DCCPY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DCCPY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DCCPY
Annual income on $10K today (after 15% tax)
$427.31/yr
After 10yr DRIP, annual income (after tax)
$107,632.46/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, DCCPY beats the other by $86,576.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DCCPY + ABBV for your $10,000?

DCCPY: 50%ABBV: 50%
100% ABBV50/50100% DCCPY
Portfolio after 10yr
$189.3K
Annual income
$75,699.09/yr
Blended yield
39.98%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DCCPY
No analyst data
Altman Z
5.7
Piotroski
7/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DCCPY buys
0
ABBV buys
0
No recent congressional trades found for DCCPY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDCCPYABBV
Forward yield5.03%3.06%
Annual dividend / share$1.49$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR41.9%40.6%
Portfolio after 10y$276.3K$102.3K
Annual income after 10y$126,626.42$24,771.77
Total dividends collected$238.3K$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DCCPY vs ABBV ($10,000, DRIP)

YearDCCPY PortfolioDCCPY Income/yrABBV PortfolioABBV Income/yrGap
1$11,413$713.36$11,550$430.00$137.00ABBV
2$13,292$1,079.75$13,472$627.96$180.00ABBV
3$15,890$1,667.63$15,906$926.08$16.00ABBV
4← crossover$19,646$2,643.83$19,071$1,382.55+$575.00DCCPY
5$25,356$4,334.96$23,302$2,095.81+$2.1KDCCPY
6$34,551$7,419.80$29,150$3,237.93+$5.4KDCCPY
7$50,378$13,408.05$37,536$5,121.41+$12.8KDCCPY
8$79,831$25,926.30$50,079$8,338.38+$29.8KDCCPY
9$139,903$54,483.99$69,753$14,065.80+$70.2KDCCPY
10$276,322$126,626.42$102,337$24,771.77+$174.0KDCCPY

DCCPY vs ABBV: Complete Analysis 2026

DCCPYStock

DCC plc provides sales, marketing, and support services worldwide. The company's DCC LPG segment sells and markets liquefied petroleum gas (LPG), refrigerants, and natural gas. Its DCC Retail & Oil segment markets, sells, and retails transport and commercial fuels, heating oils, and related products and services; operates retail petrol stations; resells fuel cards; distributes oil; and provides inbound logistics, storage and filling, and outbound logistics services. This segment serves domestic, agricultural, commercial/industrial, forecourt, aviation, and marine customers. The company's DCC Healthcare segment offers products and services to healthcare providers, and health and beauty brand owners; outsourced contract manufacturing services to the health and beauty sector; nutrition products, such as vitamins and health supplements; beauty products; and product development, formulation, manufacturing, and packaging services. In addition, this segment procures and sells exempt medicinal products. Its DCC Technology segment distributes consumer technology products, including smart home products, gaming consoles, peripherals and software, wearable technology, and accessories; business and enterprise technology products, such as tablets, notebooks, and PCs; networking and security products; communication products comprising smartphones; and servers and storage products, audio visual products, printers, peripherals, cables and connectors, and consumables to retailers, resellers, and integrators. It also provides supply chain services. The company was founded in 1976 and is headquartered in Dublin, Ireland.

Full DCCPY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DCCPY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DCCPY vs SCHDDCCPY vs JEPIDCCPY vs ODCCPY vs KODCCPY vs MAINDCCPY vs JNJDCCPY vs MRKDCCPY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.